open access
Direct costs of hypertension treatment - primary study
open access
Abstract
Background Arterial hypertension (AH) is one of the most widespread diseases of the contemporary civilization in the world. The improper lifestyle of the contemporary society (rich-fat diet, low physical activity, alcohol abuse, increase in salt intake and smoking cigarettes) is the main cause of the progress of arterial hypertension.
In Poland 29% of adult population suffers from arterial hypertension. The results of the nationwide research NATPOL PLUS shows that 62% of subjects take hypotensive medicines systematically, 19% irregularly and almost 19% didn’t adopt the proposed treatment.
The analysis of the costs of arterial hypertension therapy delivers information about the size of the burden of the health system and also the patient himself. The aim of the research was the analysis of the direct costs of pharmacotherapy, medical visits, laboratory tests, the costs of associated with the purchase of ancillary equipment of the patient with arterial hypertension, who was monitored in one of the largest pharmacies of the city of Poznan.
Material and methods The research was conducted initially in 20 patients with diagnosed and treated arterial hypertension in the age group from 37 to 61 years during the 12 months.
Results The total cost of the arterial hypertension therapy was 46,568.02 PLN which means that one person represents a value of 2328.40 PLN.
Conclusions The analysis of the direct costs showed that the pharmacotherapy costs paid by a patient are almost three times higher in comparison with the expenses of the taxpayer (NFZ).
Arterial Hypertension 2010, vol. 14, no 6, pages 460-473
Abstract
Background Arterial hypertension (AH) is one of the most widespread diseases of the contemporary civilization in the world. The improper lifestyle of the contemporary society (rich-fat diet, low physical activity, alcohol abuse, increase in salt intake and smoking cigarettes) is the main cause of the progress of arterial hypertension.
In Poland 29% of adult population suffers from arterial hypertension. The results of the nationwide research NATPOL PLUS shows that 62% of subjects take hypotensive medicines systematically, 19% irregularly and almost 19% didn’t adopt the proposed treatment.
The analysis of the costs of arterial hypertension therapy delivers information about the size of the burden of the health system and also the patient himself. The aim of the research was the analysis of the direct costs of pharmacotherapy, medical visits, laboratory tests, the costs of associated with the purchase of ancillary equipment of the patient with arterial hypertension, who was monitored in one of the largest pharmacies of the city of Poznan.
Material and methods The research was conducted initially in 20 patients with diagnosed and treated arterial hypertension in the age group from 37 to 61 years during the 12 months.
Results The total cost of the arterial hypertension therapy was 46,568.02 PLN which means that one person represents a value of 2328.40 PLN.
Conclusions The analysis of the direct costs showed that the pharmacotherapy costs paid by a patient are almost three times higher in comparison with the expenses of the taxpayer (NFZ).
Arterial Hypertension 2010, vol. 14, no 6, pages 460-473
Keywords
arterial hypertension; direct costs; time horizon; perspectives; patients; primary study
About this articleTitle
Direct costs of hypertension treatment - primary study
Journal
Issue
Article type
Original paper
Pages
460-473
Published online
2011-01-14
Page views
1005
Article views/downloads
3216
Bibliographic record
Nadciśnienie tętnicze 2010;14(6):460-473.
Keywords
arterial hypertension
direct costs
time horizon
perspectives
patients
primary study
Authors
Alicja Wassel
Elżbieta Nowakowska
Wiesław Bryl
Krzysztof Kus
Anna Paczkowska